Shock, Pressors, and Inotropes
SHOCK, PRESSORS, AND INOTROPES
Shock
- Definition: Syndrome initiated by acute systemic hypoperfusion, leading to tissue hypoxia and vital organ dysfunction, or perfusion inadequate to meet metabolic demands of the tissue.
- Types:
1. Hypovolemic – hemorrhagic vs nonhemorrhagic
2. Obstructive – mechanical obstruction to cardiac ouput; examples include cardiac tamponade, pulmonary emboli, tension pneumothorax
3. Cardiogenic – primary pump failure; can be secondary to reduced contractility (cardiomyopathy), ventricular outflow tract obstr. (pulmonary emboli, AS), ventricular filling defects (MS), valvular failure, dysrhythmias, etc.
4. Distributive – maldistribution of blood flow; best example is sepsis but can be seen with liver dysfx, hyperthyroidism, etc.
a. Neurogenic – autonomic dysfunction secondary to CNS injury above the upper thoracic level; sec to autonomic dysfunction and is characterized by hypotension, bradycardia, and warm skin.
5. Spinal – sec to decreased sympathetic outflow from higher centers
Monitoring and Diagnosis of Shock
- Vital Signs:
Heart Rate – bradycardia (neurogenic), tachycardia (except those on B-blockers, or with pacers)
BP – widened pulse pressure with distributive shock
Urine output – one of the earliest signs of inadequate perfusion at the tissue level
4. Other – mental status, skin turgor, etc
- Laboratory Evaluation
1. Base Deficit – Normal = -3 ( +3
2. Lactate levels – secondary to increased anaerobic metabolism or decreased excretion through kidney
3. Intramucosal pH monitoring
- Invasive hemodynamic monitoring; venous SaO2
MANAGEMENT OF SHOCK; PRESSORS AND INOTROPES
Physiology of Shock: Oxygen Transport
-- Delivery of O2 (DO2) = Cardiac Index (CI) x O2 Content (CaO2)
Normal values = 620 +/- 50 ml/min/m2
-- CaO2 = (1.34 x Hgb x SaO2) + (0.0031 x PaO2)
-- Cardiac Output
CO = HR x SV; Normal CI = 3.5 – 5.5 L/min/m2
Stroke volume is determined by preload, afterload, and contractility
Initial Management
-- Restoration of intravascular volume; crystalloid vs colloid
-- Improve O2- carrying capacity
-- Improvement of perfusion, i.e. inotropes
Receptor physiology
1- Adrenergic receptors
-- Cell membrane glycoproteins;
-- 2 types – α and β further subdivided into 2 subtypes
-- All but α1 involve cAMP as the second messenger: receptor bound ---- G-protein stimulated ---- GDP released, GTP binds to G-protein ---- adenylyl cyclase stimulated or inhibited (depending on the receptor and G protein) -- ATP conversion to cAMP stimulated or inhibited which affects other protein kinases ---- phosphorylation of other proteins that alter intracellular Ca++
−− α 1 receptors: receptor bound ---- Gq protein stimulated ---- phospholipase C activated ---- DAG and IP3 incr ---- further protein phosphorylation and alterations in intracellular Ca++
− α 1 -- vasoconstrict – present on postsynaptic sympathetic nerves
− α 2 -- vasodilate and neg chronotropy -- present on presynaptic sympathetic nerves and acts as feedback inhibition
− β1 -- incr cardiac fx (inotropy, chronotropy, dromotropy), renin release, etc -- β2 -- affects vascular and bronchiolar tone by relaxing smooth muscle
2- Dopaminergic receptors
-- Also glycoproteins with 2 subtypes
-- Also act on adenylate cyclase and affect cAMP levels
-- DA1 – postsynaptic receptors located in renal, splanchnic, coronary and cerebral vascular beds, etc; stimulation results in smooth muscle relaxation
-- DA2 – presynaptic receptors located in carotid body; decrease afferent neural input to CNS and decrease hypoxic ventilatory drive (which has implications in pts with decreased CO2 responsiveness)
3 - Regulation of receptors
-- Desensitization occurs from prolonged exposure, which leads to decreased numbers of receptors, uncoupling of receptors from adenylate cyclase, and changes in second messenger concentrations.
-- Peripheral vascular responses to adrenergic agonists develop at different rates and ages so there will be variability in responses
-- Corticosteroids and thyroid hormone --- increase β density
-- Transplanted heart and those with chronic CHF – downregulated β receptor activity
-- Hypoxia – down regulation of β receptors in myocardium over time
Vasoactive Adrenergic and Dopaminergic Agents
1 - Epinephrine
-- Potent α and β1 agonism and moderate β2 agonism
-- At lower doses (0.04-0.1 mcg/kg/min), β effects predominate (incr CO, HR, decr SVR, etc)
-- At higher doses, vasoconstriction and venoconstriction
-- Potent renal/splanchnic vasoconstrictor even at low doses (countered by incr CO)
-- Also increases glucose and renin activity
-- Indication: useful in providing inotropic support in pts with severe CV collapse particularly in those unresponsive to Dp
-- T½ = 3 minutes; dose = 0.1-1.0 mcg/kg/min
2 - Norepinephrine
-- Potent β1 agonist and α agonism – (+) inotropy and vasoconstrictor
-- Increases BP – systolic > diastolic, CO unchanged or decreased
-- Decreases renal and mesenteric perfusion and increases afterload
-- Major indications: hyperdynamic shock that does not respond to volume or Dp
-- T½ = 2 minutes; dose = 0.05-0.1 mcg/kg/min
-- Adverse rxns: local infiltrate, which can cause necrosis – tx’d with phentolamine
3 - Dopamine
-- Naturally occurring precursor of NE; also induces its release
-- Has a dose dependent effect on α, β, and DA receptors:
-- < 2-5 mcg/kg/min stimulate DA1 receptors to incr renal, mesenteric, cerebral, and coronary perfusion
-- 5-10 mcg/kg/min lead to β agonism – incr HR, contractility, SV with little effect on SVR ( increases CO
-- >10 mcg/kg/min leads to predominating α effects with vaso- and venoconstriction; also decr mesenteric and renal perfusion, incr coronary resistance and myocardial work
-- Also can increase pulm art pressures and resistance in those with pulm HTN; can exacerbate hypoxic pulm vasoconstriction
-- Indication: used for decreased CO, BP, or for augmentation of RBF
-- T½ = 2 minutes; dose =1-20 mcg/kg/min
4 - Dobutamine
-- synthetic catecholamine
-- β- selective (mainly β1) but l-isomer has little α effects
-- Increases contractility and HR with some decr in SVR
-- Indications: used in pts with low CO states
-- T½ = 2 min; dose =1-20 mcg/kg/min
| |α1 |α2 |β1 |β2 |DA |
|Epi |+++ |+++ |+++ |+++ |- |
|NE |+++ |+++ |+++ |+ |- |
|Dp |- to +++ |+ |++ to +++ |++ |+++ |
|Db |- to + |- |+++ |+ |- |
5 - Isoproterenol
-- Pure β agonism – increased inotropy/chronotropy and vasodilates (increased pulse pressure because of a rise in SBP and a decr in DBP)
-- Also acts as a pulmonary vasodilator
-- Indications – may be used in low cardiac output states but tachycardia and decr preload may compromise CO; can be used for bradycardia
-- T½ =1.5 min; dose = 0.05-0.1 mcg/kg/min
6 - Phenylephrine
-- Synthetic α1 agonist
-- Indications – useful in spinal shock, hyperdynamic shock, TET spells
-- Dose = 0.1-0.5 mcg/kg/min
Other Vasoactive Agents
1 - Amrinone
-- Bypyridine derivative with marked vasodilator effects and slight (+)inotropy
-- Phosphodiesterase inhibitor that increases cAMP and intracellular Ca+
-- Side effects: LFT abnormalities and decreases platelets
-- Dose= 3-10 mcg/kg/min
2 - Milrinone
-- 15x more inotropy than Amrinone with similar vasodilation
-- Increases coronary perfusion, CO, skeletal muscle perfusion and splanchnic perfusion
-- Indications: useful in pts with CHF, cardiogenic shock, hypodynamic septic shock, β receptor down regulation
-- Dose= 0.25-0.75 mcg/kg/min
3 - Nitroprusside
-- Mechanism not completely understood but appears to be similar to NO, which increases cGMP by activation of cGMP kinase that subsequently decreases intracellular Ca++
-- Dilates arteries and veins – has variable effects on CO
-- Indication: hypertensive emergencies, severe cardiogenic shock
-- Disadvantages: nonselective vasodilator so theoretically should not be used with increased ICP, also lose hypoxic pulmonary vasoconstriction
Metabolized into CN and metHgb (methylene blue contraindicated)
-- Dose= 0.25-8 mcg/kg/min; duration=1-5 minutes
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- vasopressors and inotropes made easy
- pressors made easy
- vasopressors and inotropes review
- inotropes and vasopressors pdf icu
- list of inotropes and vasopressors
- vasopressors and inotropes chart
- inotropes and vasopressors ncbi
- inotropes and vasopressors
- pressors medication
- pressors medication list
- pressors medication icu
- pressors in icu